Clinical applications of pharmacologic therapies for spinal cord injury.

We review the evidence supporting the role of glucocorticosteroids, trilazad, and GM1 ganglioside in spinal cord injury and provide our critique of the published studies, along with our recommendations for pharmacologic therapy for this complex and difficult problem.
AuthorsS M Zeidman, G S Ling, T B Ducker, R G Ellenbogen
JournalJournal of spinal disorders (J Spinal Disord) Vol. 9 Issue 5 Pg. 367-80 (Oct 1996) ISSN: 0895-0385 [Print] United States
PMID8938604 (Publication Type: Journal Article, Review)
Chemical References
  • Calcium Channel Blockers
  • Free Radical Scavengers
  • Glucocorticoids
  • Neuroprotective Agents
  • Pregnatrienes
  • U 74389F
  • Naloxone
  • G(M1) Ganglioside
  • 4-Aminopyridine
  • Methylprednisolone
  • 4-Aminopyridine (therapeutic use)
  • Animals
  • Calcium Channel Blockers (therapeutic use)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Evaluation, Preclinical
  • Free Radical Scavengers (therapeutic use)
  • G(M1) Ganglioside (therapeutic use)
  • Glucocorticoids (therapeutic use)
  • Humans
  • Methylprednisolone (administration & dosage, adverse effects, therapeutic use)
  • Multicenter Studies as Topic
  • Naloxone (therapeutic use)
  • Neuroprotective Agents (administration & dosage, adverse effects, classification, therapeutic use)
  • Pregnatrienes (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Spinal Cord Injuries (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: